SageView Advisory Group
SLS icon

SageView Advisory Group’s SELLAS Life Sciences SLS Stock Holding History

SageView Advisory Group’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,000
Closed -$18.9K – 2127
2025
Q4 		$18.9K Buy
+5,000
New +$9.72K ﹤0.01% 1480

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

SageView Advisory Group's SLS Position: Q1 2026 in Review

SageView Advisory Group sold out of SELLAS Life Sciences (SLS) in Q1 2026, closing a stake of 5,000 shares — an estimated $18.9K sold.

SageView Advisory Group first reported a position in SLS in Q4 2025 and held it in 1 quarter. The position peaked at $18.9K in Q4 2025. 160 funds tracked by Wall St. Rank hold SLS as of Q1 2026.

  • SageView Advisory Group reported no remaining SELLAS Life Sciences position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 5,000 SELLAS Life Sciences shares in Q1 2026, an estimated $18.9K.
  • SageView Advisory Group first reported a position in SELLAS Life Sciences in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's SELLAS Life Sciences position peaked at $18.9K in Q4 2025.
  • 160 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.